Loading stock analysis…
Evidence Synthesis
Last synthesized: 21 Oct 2026, 07:41
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
JOHN PHARMA SEES SIGNIFICANT IMPROVEMENT IN GROSS MARGIN AND CLOSE PRICE ACROSS Q3 2026, DESPITE A DECLINE IN DAILY VOLUME.
Gross margin accelerated to , up from -2605.31%. Meanwhile, close price accelerated to , up from 0.4 INR.
However, daily volume decelerated to , down from 681,152 shares.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 100 % | -2,605.31 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -2,605.31 % | 0 | ▼ |
| PRICE_CHANGE_PERCENT | 2.5 % | — | - |
| DAILY_VOLUME | 3,70,966 shares | 6,81,152 | ▼ |
| CLOSE_PRICE | 0.41 INR | 0.4 | ▲ |
Cite this
Source: Samhati evidence synthesis for JOHNPHARMA (2026-10-21). Observation: JOHN PHARMA SEES SIGNIFICANT IMPROVEMENT IN GROSS MARGIN AND CLOSE PRICE ACROSS Q3 2026, DESPITE A DECLINE IN DAILY VOLUME. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/johnpharma
Filing step-changes